The study of Estrogen Receptor Positive (ER plus) Breast Cancer-Treatment Landscape and Competitive Analysis, 2017 is very important to enhance business productivity and for the study of market forecast. This New Report presented by Orbis Reseach contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
“Estrogen Receptor Positive (ER+) Breast Cancer – Treatment Landscape & Competitive Analysis, 2017”, report provides comprehensive insights about the treatment landscape across this indication. This report also provides the deep understanding of the stages of the Estrogen Receptor Positive (ER+) Breast Cancer, epidemiology, risk factors, diagnosis etc. A key objective of the report is to establish the understanding of the treatment landscape and competitive analysis of the Estrogen Receptor Positive (ER+) Breast Cancer which mainly describes the treatment of breast cancer at different stages. Breast cancer is the condition where the cells of the breast area become tumorous, that is, they undergo unlimited cell division. Both women and men are affected but chances of men being diagnosed with breast cancer are rare. Each year about 2,300 new cases of breast cancer in men and about 230,000 new cases in women are diagnosed. It is the second most common cancer among women in USA.
Attractive Discount Details on Purchase of This Report:
Get Flat 15% on Single User License, Flat 25% on Site License & Flat 30% on Enterprise Licence
offer Last 30th June
Get a PDF Sample of Report at: http://www.orbisresearch.com/contacts/request-sample/209353 .
This report provides the insights of the marketed drugs for the Estrogen Receptor Positive (ER+) Breast Cancer which includes the Targeted Therapy, Hormone Therapy and Chemotherapy. In case of Estrogen Receptor Positive (ER+) Breast Cancer, Hormone therapy is the main focus of treatment after surgery and chemotherapy. Hormonal therapy is usually recommended after 5 years of surgery and can be divided into Estrogen blocking hormonal therapy and estrogen lowering hormonal therapy based on the mechanism of action of the hormonal therapy drugs. Of all the late-stage pipeline drugs, Buparlisib is expected to reach the market in the next few years.
Recent report of covers the treatment landscape which provides the treatment options by different stages and type of the breast cancer. There are four chemotherapy drugs, six hormone therapy drugs and one targeted therapy drugs in market for the treatment of Estrogen Receptor Positive (ER+) Breast Cancer.
Place a Purchase Order for this Report at: http://www.orbisresearch.com/contact/purchase/209353 .
- The new report, provides a Estrogen Receptor Positive (ER+) Breast Cancer Treatment Landscape across the globe
- The report provides profiles of the marketed drug which includes the product description, cost of treatment, development partner, patent expiry date, sales data etc.
- Comparative analysis of marketed drugs by therapy, cost of treatment, Therapeutic Class. Coverage of the Estrogen Receptor Positive (ER+) Breast Cancer Phase III and Pre-registration Drugs Analysis by product type, molecule type, route of administration, Median Progression Free Survival
- The report reviews key players involved in the therapeutics development for Estrogen Receptor Positive (ER+) Breast Cancer and also provide market barriers, market drivers and opportunities
- Provides Phase III products assessment by line of therapy and target.
Got any Query? Feel free to ask us at : http://www.orbisresearch.com/contacts/enquiry-before-buying/209353
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +9164101019
Follow Us on LinkedIn: https://www.linkedin.com/company/orbis-research